Selected Grants
GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that Harbor the p53 R175H Mutation
Clinical TrialPrincipal Investigator · Awarded by Clasp Therapeutics, Inc · 2025 - 2030A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator-controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcino
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2029Xencor: ENPP3 BiTe study for ccRCC
Clinical TrialPrincipal Investigator · Awarded by Xencor, Inc · 2023 - 2028BionNTech BNT142-01 (CLDN6+ solid tumors)
Clinical TrialPrincipal Investigator · Awarded by BioNTech SE · 2023 - 2028Tyra-Surf-301
Clinical TrialPrincipal Investigator · Awarded by Tyra Biosciences, Inc. · 2023 - 2028A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9?Engineered T Cells (CTX131) in Adult Subjects with Relapsed or Refractory Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by CRISPR Therapeutics · 2023 - 2028Synthekine STK-012
Clinical TrialPrincipal Investigator · Awarded by Synthekine · 2023 - 2027PT-112 in mCRPC (Phase 2 expansion; Phosplatin Therapeutics)
Clinical TrialPrincipal Investigator · Awarded by Promontory Therapeutics · 2022 - 2026An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2020 - 2026DoD: PCRP Clinical Consortium: Duke University Clinical Research Site
ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026Keynote B15 - EV/Pembro vs GEM/CIS in muscle-invasive bladder cancer
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2022 - 2026Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site
ResearchCo Investigator · Awarded by Department of Defense · 2021 - 2025NeoImmune NMTNT110
Clinical TrialPrincipal Investigator · Awarded by NeoImmuneTech, Inc. · 2020 - 2025Aravive 003: AVB-S6-500 A phase 1b/2 study of AVB-S6-500 in combination with cabozantinib, AVB-S6-500 in combination with cabozantinib and nivolumab, and AVB-S6-500 monotherapy in patients with advanced of metastatic clear cell renal cell carcinoma
Clinical TrialPrincipal Investigator · Awarded by Aravive, Inc · 2022 - 2025Merck U04B
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2023 - 2025A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific -T cell engager, alone or with low dose interleukin-2 or Pe
Clinical TrialPrincipal Investigator · Awarded by LAVA Therapeutics N.V. · 2024 - 2025Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
ResearchPrincipal Investigator · Awarded by Case Western Reserve University · 2020 - 2025A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
Clinical TrialPrincipal Investigator · Awarded by Mirati Therapeutics, Inc. · 2019 - 2024A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects with Previously Treated Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Bellicum Pharmaceuticals, Inc. · 2022 - 2022External Relationships
- Astellas Pharma Inc.
- Bristol Myers Squibb
- Eisai
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Pfizer Inc.
- Seattle Genetics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.